Your browser doesn't support javascript.
loading
Ultrasonic Microbubble Cavitation Deliver Gal-3 shRNA to Inhibit Myocardial Fibrosis after Myocardial Infarction.
Li, Wenqu; Jin, Qiaofeng; Zhang, Li; He, Shukun; Song, Yishu; Xu, Lingling; Deng, Cheng; Wang, Lufang; Qin, Xiaojuan; Xie, Mingxing.
Afiliação
  • Li W; Department of Ultrasound Medicine, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, 1277 Jiefang Ave., Wuhan 430022, China.
  • Jin Q; Hubei Province Clinical Research Center for Medical Imaging, Wuhan 430022, China.
  • Zhang L; Hubei Province Key Laboratory of Molecular Imaging, Wuhan 430022, China.
  • He S; Department of Ultrasound Medicine, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, 1277 Jiefang Ave., Wuhan 430022, China.
  • Song Y; Hubei Province Clinical Research Center for Medical Imaging, Wuhan 430022, China.
  • Xu L; Hubei Province Key Laboratory of Molecular Imaging, Wuhan 430022, China.
  • Deng C; Department of Ultrasound Medicine, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, 1277 Jiefang Ave., Wuhan 430022, China.
  • Wang L; Hubei Province Clinical Research Center for Medical Imaging, Wuhan 430022, China.
  • Qin X; Hubei Province Key Laboratory of Molecular Imaging, Wuhan 430022, China.
  • Xie M; Department of Ultrasound Medicine, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, 1277 Jiefang Ave., Wuhan 430022, China.
Pharmaceutics ; 15(3)2023 Feb 22.
Article em En | MEDLINE | ID: mdl-36986588
Galectin-3 (Gal-3) participates in myocardial fibrosis (MF) in a variety of ways. Inhibiting the expression of Gal-3 can effectively interfere with MF. This study aimed to explore the value of Gal-3 short hairpin RNA (shRNA) transfection mediated by ultrasound-targeted microbubble destruction (UTMD) in anti-myocardial fibrosis and its mechanism. A rat model of myocardial infarction (MI) was established and randomly divided into control and Gal-3 shRNA/cationic microbubbles + ultrasound (Gal-3 shRNA/CMBs + US) groups. Echocardiography measured the left ventricular ejection fraction (LVEF) weekly, and the heart was harvested to analyze fibrosis, Gal-3, and collagen expression. LVEF in the Gal-3 shRNA/CMB + US group was improved compared with the control group. On day 21, the myocardial Gal-3 expression decreased in the Gal-3 shRNA/CMBs + US group. Furthermore, the proportion of the myocardial fibrosis area in the Gal-3 shRNA/CMBs + US group was 6.9 ± 0.41% lower than in the control group. After inhibition of Gal-3, there was a downregulation in collagen production (collagen I and III), and the ratio of Col I/Col III decreased. In conclusion, UTMD-mediated Gal-3 shRNA transfection can effectively silence the expression of Gal-3 in myocardial tissue, reduce myocardial fibrosis, and protect the cardiac ejection function.
Palavras-chave

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Idioma: En Revista: Pharmaceutics Ano de publicação: 2023 Tipo de documento: Article

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Idioma: En Revista: Pharmaceutics Ano de publicação: 2023 Tipo de documento: Article